StreetInsider.com News Articles

Form 424B3 Silexion Therapeutics

Thu, 18 Jun 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260618/26663950.html

Form 424B3 Silexion Therapeutics

Thu, 18 Jun 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260618/26663950.html

Form DEF 14A Silexion Therapeutics For: Jun 16

Tue, 16 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260616/26654809.html

Form DEF 14A Silexion Therapeutics For: Jun 16

Tue, 16 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260616/26654809.html

Form S-3 Silexion Therapeutics

Fri, 12 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26640722.html

Form S-3 Silexion Therapeutics

Fri, 12 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260612/26640722.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Shirvan Mitchell

Mon, 08 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260608/26617290.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Shirvan Mitchell

Mon, 08 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260608/26617290.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Horenshtein Hadar Mirit

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617235.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Horenshtein Hadar Mirit

Mon, 08 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260608/26617235.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Hadar Ilan

Mon, 08 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260608/26617190.html

Form 4 Silexion Therapeutics For: Jun 04 Filed by: Hadar Ilan

Mon, 08 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260608/26617190.html

Form PRE 14A Silexion Therapeutics For: Jun 03

Wed, 03 Jun 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260603/26600004.html

Form PRE 14A Silexion Therapeutics For: Jun 03

Wed, 03 Jun 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260603/26600004.html

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Fri, 29 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26574855.html

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Fri, 29 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26574855.html

Form 8-K Silexion Therapeutics For: May 29

Fri, 29 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26570695.html

Form 8-K Silexion Therapeutics For: May 29

Fri, 29 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26570695.html

Form S-8 Silexion Therapeutics

Thu, 28 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260528/26567235.html

Form S-8 Silexion Therapeutics

Thu, 28 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260528/26567235.html

Form 8-K Silexion Therapeutics For: May 26

Tue, 26 May 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260526/26546608.html

Form 8-K Silexion Therapeutics For: May 26

Tue, 26 May 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260526/26546608.html

Silexion Therapeutics announces 1-for-10 reverse share split

Tue, 26 May 2026 08:30:18 -0400

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, with trading on a split-adjusted basis beginning at market open on May 29, 2026.

Under the reverse share split, every ten ordinary shares issued and outstanding will be automatically combined into one share. The par value will increase proportionately from $0.0135 per share to $0.135 per share. No fractional shares will be issued, and shareholders entitled to fractional shares through the DTC system will receive a rounded-up whole share.

The company stated the

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Tue, 26 May 2026 08:30:00 -0400

Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204.

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company’s ordinary shares will begin trading on a

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Tue, 26 May 2026 08:30:00 -0400